2024 / 06

Next Paper
DOI: 10.24075/brsmu.2024.059
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Transcription profile in preoperative aromatase inhibitor response test in breast cancer patients

Burmenskaya OV, Trofimov DYu, Kometova VV, Rodionova MV, Rodionov VV
About authors

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

Correspondence should be addressed: Olga Vladimirovna Burmenskaya
Akademika Oparina, 4, Moscow, 117997, Russia; ur.liam@aksnemruob

About paper

Funding: the study was partially supported under the State Task "Personification of adjuvant treatment of patients with luminal HER2-negative subtypes of breast cancer enabled by a preoperative hormone sensitivity test" (state registry number in the Unified State R&D Efforts Registration System (EGISU NIOKTR): 124020600031-3).

Author contribution: VV Rodionov — study conceptualization and design; MV Rodionova, VV Kometova — material collection and processing; DYu Trofimov, OV Burmenskaya — PCR testing; OV Burmenskaya — analysis of the results, statistical processing of the data, manuscript authoring; VV Rodionov, DYu Trofimov — editing.

Compliance with ethical standards: the study was approved by the Committee on Biomedical Ethics of V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology (Minutes #03 of March 21, 2024). All patients signed an informed consent to participate in the study.

Received: 2024-11-08 Accepted: 2024-12-05 Published online: 2024-12-21
|
  1. Ahn SG, Nam SJ, Ahn SH, Jung Y, Park HK, Lee SJ, et al. Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). J Breast Cancer. 2021; 24 (2): 164–74. DOI: 10.4048/jbc.2021.24.e17.
  2. Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023; 24 (7): 6834. DOI: 10.3390/ijms24076834.
  3. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019; 380 (25): 2395–405. Available from: https://doi.org/10.1056/NEJMoa1904819.
  4. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021; 32 (10): 1216–35. Available from: https://doi.org/10.1016/j.annonc.2021.06.023.
  5. Zolotoj standart profilaktiki, diagnostiki, lechenija i reabilitacii bol'nyh RMZh. Rossijskoe obshhestvo onkomammologov. 2024; 297 s. Russian.
  6. Tjuljandin SA, Stenina MB, Frolova MA. Prakticheskie instrumenty, oblegchajushhie vybor ad#juvantnoj lekarstvennoj terapii u bol'nyh operabel'nym ljuminal'nym HER2-negativnym rakom molochnoj zhelezy. Zlokachestvennye opuholi. 2024; 14 (2): 51– 57. Dostupno po ssylke: https://doi.org/10.18027/2224-5057-2024-003. Russian.
  7. Bozhenko VK, Trocenko ID , Kudinova EA, Vardanjan SG, Zaharenko MV, Solodkij VA, Makarova MV. Vozmozhnosti tipirovanija raka molochnoj zhelezy s ispol'zovaniem metodiki OT-PCR. Sibirskij onkologicheskij zhurnal. 2019; 18 (5): 61–67. DOI: 10.21294/1814-4861-2019-18-5-61-67. Russian.
  8. Burmenskaya OV, Trofimov DYu, Kometova VV, Sergeev IV, Maerle AV, Rodionov VV, i dr. Razrabotka i opyt ispol'zovanija transkripcionnoj signatury genov v diagnostike molekuljarnyh podtipov raka molochnoj zhelezy. Akusherstvo i ginekologija. 2020; 2: 132–140. Dostupno po ssylke: https://dx.doi.org/10.18565/aig.2020.2.132-140. Russian.
  9. Krasilnikov MA, Shherbakov AM. Signal'nye puti, reguliruemye jestrogenami, i ih rol' v opuholevoj progressii: novye fakty i napravlenija poiska. Uspehi molekuljarnoj onkologii. 2014; 1: 18–26. Russian.
  10. Dovzhikova IV, Andrievskaja IA. Receptory jestrogenov (obzor literatury). Chast' 1. Bjulleten' fiziologii i patologii dyhanija. 2019; 72: 120–27. DOI: 10.12737/article_5d0ad2e5d54867.15780111. Russian.
  11. Gregory KJ, Roberts AL, Conlon EM, Mayfield JA, Hagen MJ, Crisi GM, et al. Gene expression signature of atypical breast hyperplasia and regulation by SFRP1. Breast Cancer Res. 2019; 21 (1): 76. DOI: 10.1186/s13058-019-1157-5.
  12. Kumar M, Salem K, Jeffery JJ, Yan Y, Mahajan AM, Fowler AM. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation. J Nucl Med. 2021; 62 (4): 500–506. DOI: 10.2967/jnumed.120.249508. Epub 2020 Aug 28.